Carved up ownership of Russia’s Biocad planned by Pharmstandard and Millhouse

23 May 2014

Russia’s largest pharma company Pharmstandard (PHST: RU) and Millhouse, an investment company owned by Russian billionaire Roman Ambromovich (in some quarters best known as the owner of the UK premier League football club Chelsea), have announced plans to acquire significant stakes (individually) in Biocad Holding, the main shareholder in biotechnological company CJSC Biocad, Russia’s largest biotech firm, which has recently been in the news for getting regulatory approval of some blockbuster biological biosimilars (The Pharma Letters passim).

Biocad specializes in the development, production and promotion of original and generic drugs in the following therapeutic categories: urology, gynecology, dermatovenerology, oncology, hematology, autoimmune and infectious diseases.

Millhouse to own 50% of the company

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK